Skip to content
10-Q

Quarterly Report

MAZE THERAPEUTICS, INC. MAZE

0001193125-26-219430

← back to feed
Filed
May 12, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 7, 2026 55.35M sh
Shares Diluted Q1 2026 · Mar 31, 2026 53.9M sh
Shares Diluted Q1 2026 · Mar 31, 2025 28.63M sh
Capex Q1 2026 · Mar 31, 2026 $93K
Capex Q1 2026 · Mar 31, 2025 $299K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$39.11M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$29.52M
Long Term Debt Q1 2026 · Mar 31, 2026 $38.83M
Short Term Debt Q1 2026 · Mar 31, 2026 $0
Cash And Equivalents Q1 2026 · Mar 31, 2026 $198.77M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $189.25M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $294.37M
Stockholders Equity Q1 2026 · Mar 31, 2026 $341.7M
Stockholders Equity Q1 2026 · Dec 31, 2025 $354.97M
Current Liabilities Q1 2026 · Mar 31, 2026 $21.24M
Current Liabilities Q1 2026 · Dec 31, 2025 $22.56M
Total Liabilities Q1 2026 · Mar 31, 2026 $78.01M
Total Liabilities Q1 2026 · Dec 31, 2025 $42.16M
Current Assets Q1 2026 · Mar 31, 2026 $379.78M
Current Assets Q1 2026 · Dec 31, 2025 $349.72M
Total Assets Q1 2026 · Mar 31, 2026 $419.71M
Total Assets Q1 2026 · Dec 31, 2025 $397.13M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.45
Eps Diluted Q1 2026 · Mar 31, 2025 −$1.15
Eps Basic Q1 2026 · Mar 31, 2026 −$0.45
Eps Basic Q1 2026 · Mar 31, 2025 −$1.15
Sga Expense Q1 2026 · Mar 31, 2026 $12.41M
Sga Expense Q1 2026 · Mar 31, 2025 $7.82M
Rd Expense Q1 2026 · Mar 31, 2026 $34.15M
Rd Expense Q1 2026 · Mar 31, 2025 $27.58M
Net Income Q1 2026 · Mar 31, 2026 −$24.21M
Net Income Q1 2026 · Mar 31, 2025 −$32.79M
Operating Income Q1 2026 · Mar 31, 2026 −$26.55M
Operating Income Q1 2026 · Mar 31, 2025 −$35.4M
Revenue Q1 2026 · Mar 31, 2026 $20M